Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Healthcare spending

Where the money goes, and what happens when it runs short. This coverage follows budgets, cost growth, pricing pressure and the trade-offs health systems make under them.

161 articles in this topic.

Articles in this category

NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending

11/13/2026

NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending

The NHLS governance crisis reached Parliament with R1.8 billion in irregular spending, an interim board and a disputed IP Capital consultancy.
Read Article →
SADC Pharmaceutical Pooled Procurement Charter Signed in Durban

11/13/2026

SADC Pharmaceutical Pooled Procurement Charter Signed in Durban

The Charter establishing the SADC Pharmaceuticals Pooled Procurement Services was signed in Durban on 12 November 2026, with Tanzania the first Member State to sign. #SyenzaNews #MarketAccess
Read Article →
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

11/12/2026

US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

11/9/2026

CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess
Read Article →
Medicare drug price negotiation: CMS sets permanent rules

11/9/2026

Medicare drug price negotiation: CMS sets permanent rules

The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess
Read Article →
EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment

11/4/2026

EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment

The EMA mid-year report 2026 records 485 scientific advice requests in the first half, the first joint clinical assessment under the HTA Regulation and progress on the new pharmaceutical law. #SyenzaNews #MarketAccess
Read Article →
Generic lenacapavir HIV prevention gets FDA tentative approval

11/3/2026

Generic lenacapavir HIV prevention gets FDA tentative approval

Dr. Reddy's has FDA tentative approval for generic lenacapavir HIV prevention, priced at US$40 per person per year across 120 countries. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
PBS Strategic Agreements: What Government and Industry Told Patients Before the Next Deal

11/2/2026

PBS Strategic Agreements: What Government and Industry Told Patients Before the Next Deal

Australia's PBS strategic agreements with the medicines industry expire on 30 June 2027. At a 23 October webinar, the health department, GBMA and Medicines Australia explained what the deals cover, how patients can feed in, and where industry says they have fallen short on access. #SyenzaNews #MarketAccess #HTA #PBS #Australia
Read Article →
Labor Department Finalizes PBM Fee Disclosure Rule for Large Self-Insured Plans

10/30/2026

Labor Department Finalizes PBM Fee Disclosure Rule for Large Self-Insured Plans

The US Department of Labor has finalized its PBM fee disclosure rule. From plan years beginning on or after 1 July 2027, PBMs must disclose rebates, spread compensation, copay claw-backs and per-drug net prices to large self-insured ERISA plans, report twice a year, and accept an annual audit by an auditor the plan chooses. EBSA estimates $818.4 million a year in transfers from PBMs to plans and participants. #SyenzaNews #PBM #DrugPricing #MarketAccess
Read Article →
Portugal Outpatient Medicine Spend Rises 7.9%, Led by Diabetes Drugs

10/29/2026

Portugal Outpatient Medicine Spend Rises 7.9%, Led by Diabetes Drugs

Portugal's outpatient medicine bill rose 7.9% in January to August 2026. Antidiabetics drove nearly a third of the increase, and semaglutide spend rose 54.5%. #SyenzaNews #MarketAccess #HealthEconomics
Read Article →
Individualised gene therapies for rare diseases: FDA draft guidance

10/28/2026

Individualised gene therapies for rare diseases: FDA draft guidance

The FDA's draft guidance lets sponsors add new patient-specific variants to one BLA without new trials, while CMS plans to broaden its gene therapy access model.
Read Article →
Novartis core operating income rises, 2026 outlook raised

10/27/2026

Novartis core operating income rises, 2026 outlook raised

Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess
Read Article →

Related topics